Grove’s pill for U.S. healthcare won't work

May 3, 2007 | Matt Marshall

Having survived prostate cancer and now facing a mild form of Parkinson’s disease, former Intel chairman Andy Grove has turned his analytical eye on the increasingly dysfunctional U.S. healthcare system.

Grove is a smart guy, however his recommendations are disappointingly small-scale and reflective of the inordinate faith that many high-tech aficionados place in technological “fixes” for complex phenomena. That’s what David Hamilton, writer of VentureBeat Life Sciences argues in his latest look at the healthcare debate.

Note that David is covering daily venture capital investments in healthcare companies. You can bookmark his blog here, or subscribe to his RSS feed here.

Next Story: Cavium Networks has strong IPO
Previous Story: Andy Grove's placebo pill for U.S. healthcare

Twitter

Facebook

Google Buzz

Digg

StumbleUpon

Delicious

Google

More...

About the Author, Matt Marshall

Matt launched VentureBeat in September of 2006, with the realization that no one else was covering the entrepreneurial and tech innovation scene with the velocity or depth that he was. Prior to founding VentureBeat, he covered venture capital for the San Jose Mercury News from 2001 to 2006. In 2002, Matt was awarded "Journalist of the Year" by the Northern California Society of Professional Journalists. Prior to working at the Merc, he was a correspondent for the Wall Street Journal in Bonn, Germany from 1995 to 1998, and a writer for the Washington Post in 1994. Matt holds a PhD in Government and an MA in German and European Studies from Georgetown University. In addition to VentureBeat, Matt is also the Executive Producer of DEMO, the leading launchpad event for emerging technologies.